CD133 in brain tumor: the prognostic factor

CD133 in brain tumor: the prognostic factor

CD133 has been shown to be an important stem cell factor that promotes glioma progression. However, the mechanism for CD133-mediated glioma progression has yet to be fully elucidated. In this study, we found that CD133 mRNA expression was a prognostic marker in three independent glioma patient cohorts, corroborating a putative role for CD133 in glioma progression. Importantly, we found that CD1...

Evaluation of CD133 and CD56/NCAM expression in Wilms tumor and their association with prognostic factors

Objective(s): To validate certain markers for cancer stem cell populations and their clinical importance in Wilms tumor (WT)Materials and Methods: Immunohistochemical study for CD133 and CD56/NCAM was performed on forty-six cases of WT that were diagnosed between 1999 and 2015, and the association of these markers with survival and progn...

Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.

PURPOSE Clonal evolution of cancer may be regulated by determinants of stemness, specifically self-renewal, and current therapies have not considered how genetic perturbations or properties of stemness affect such functional processes. Glioblastoma-initiating cells (GICs), identified by expression of the cell surface marker CD133, are shown to be chemoradioresistant. In the current study, we so...

Troponin as a Prognostic Factor of Brain Injury in Military Field Hospitals

Expression and prognostic value of tumor stem cell markers ALDH1 and CD133 in colorectal carcinoma

The identification of cancer stem cells (CSCs) has improved the understanding of tumor occurrence and development. According to CSC theory, colorectal carcinoma (CRC) may be derived from these few cells. Thus, markers for CSCs may lead to the identification of CSCs and investigation of the correlation with various clinicopathological features and survival time in human CRC patients. Aldehyde de...